# Efficacy of bone marrow concentrate injection in the treatment of knee osteoarthritis in the elderly

Submission date	Recruitment status	[X] Prospectively registered
24/11/2025	Not yet recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
25/11/2025	Ongoing	Results
Last Edited	Condition category	Individual participant data
25/11/2025	Musculoskeletal Diseases	[X] Record updated in last yea

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Principal investigator, Public, Scientific

#### Contact name

Dr Jorge Barbosa

#### ORCID ID

https://orcid.org/0000-0002-0856-9889

#### Contact details

Unidade Local de Saúde de Lisboa Ocidental Hospital de São Francisco Xavier Serviço de Medicina Física e de Reabilitação Estrada do Forte do Alto do Duque Lisboa Portugal 1449-005 +351 210431740 jbarbosa@ulslo.min-saude.pt

# Additional identifiers

# Study information

#### Scientific Title

Efficacy of intra-articular injection of bone marrow concentrate in the treatment of knee osteoarthritis in elderly patients

## Study objectives

Main objective: To assess the efficacy of intra-articular injection of bone marrow concentrate in the treatment of symptomatic knee osteoarthritis in elderly patients, compared with a control group treated with hyaluronic acid injection (viscosupplementation).

Secondary objective: To assess whether there is a relationship between dose and efficacy.

## Ethics approval required

Ethics approval required

# Ethics approval(s)

approved 02/06/2025, Comissão de Ética para a Saúde da Unidade Local de Saúde de Lisboa Ocidental - Health Ethics Committee of the Western Lisbon Local Health Unit (Unidade Local de Saúde de Lisboa Ocidental Hospital de Egas Moniz Rua da Junqueira, 126, Lisboa, 1349-019, Portugal; +351 210432665; anavalho@ulslo.min-saude.pt), ref: Approval code: 2025-76; RNEC registry number: 20170700050

# Primary study design

Interventional

#### Allocation

Randomized controlled trial

### Masking

Blinded (masking used)

#### Control

Active

#### **Assignment**

Parallel

#### Purpose

Treatment

#### Study type(s)

# Health condition(s) or problem(s) studied

Knee osteoarthritis

#### Interventions

After meeting elegibility criteria and signing informed consent, the participants will be assigned in 1 of 2 possible groups.

Intervention group (n = 45) - ultrasound guided iliac crest bone marrow aspiration and subsequent centrifugation, obtaining a concentrate (from which a sample is sent for analysis), followed by an ultrasound-quided injection into the knee joint

Control group (n = 45) - ultrasound-guided viscosupplementation (knee intra-articular injection of hyaluronic acid)

Participants will be randomly assigned in a 1:1 ratio to the intervention or control group using a computer-generated randomization, with different block sizes. Different investigators will be responsible for the randomization, the allocation process (with opaque sealed envelopes) and the treatment. There will be blinding of the investigators performing the assessments regarding the treatment that was administered

Besides demographic and medical background data, there will be clinical, functional and generic health status assessments, before the treatment and at 1, 3, 6, and 12 months afterwards. There will be imaging assessments before the treatment and at 6 and 12 months afterwards

Clinical assessments - knee pain Visual Analogue Scale (VAS), 10 meter walk test, Timed Up and Go Test, several knee physical exam parameters

Functional and generic health status assessment - WOMAC and EQ-5D-5L scales Imaging assessment - X-ray (Kellgren-Lawrence scale and measurements) and MRI (WORMS score and measurements)

## Intervention Type

Device

#### Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

BioCUE®, Monovisc®

# Primary outcome(s)

1. Knee pain measured using visual analogue scale (VAS) at baseline (pre-treatment) and at 1, 3, 6 and 12 months after treatment

# Key secondary outcome(s))

# Completion date

10/12/2027

# Eligibility

#### Key inclusion criteria

- 1. Primary (idiopathic) femorotibial knee osteoarthritis (medial, lateral, or medial + lateral)
- 2. Diagnosis based on the clinical + radiographic criteria of the American College of Rheumatology for idiopathic knee osteoarthritis (knee pain + osteophytes + at least 1 of the following 3 criteria: age > 50 years, stiffness < 30 minutes, crepitus)
- 3. Knee symptoms mainly attributable to femorotibial osteoarthritis (medial, lateral, or medial + lateral), confirmed on physical examination
- 4. Pain and reduced lower limb mobility mainly attributable to the knee under study
- 5. Clinical presentation with average pain  $\geq$  5 (moderately severe) on the Visual Analogue Scale (VAS) for pain, on most days in the past month
- 6. Radiographic evidence of femorotibial osteoarthritis (medial, lateral, or medial + lateral) of Kellgren–Lawrence grade II or III, on a weight-bearing AP knee radiograph of the knee under study performed within the past year
- 7. Age  $\geq$  65 years

- 8. Willingness to participate in the study and sign the informed consent
- 9. If both knees meet the inclusion criteria, the knee selected for the study will be the one with the higher average pain on most days in the past month on the Visual Analogue Scale (VAS) for pain; if pain intensity is equal in both knees, the selected knee will be the one with more frequent pain (greater number of painful days in the past month)

## Healthy volunteers allowed

No

# Age group

Senior

## Lower age limit

65 years

#### Upper age limit

120 years

#### Sex

Αll

#### Total final enrolment

0

## Key exclusion criteria

- 1. History of knee surgery and of injection with platelet-rich plasma, or with bone marrow, adipose tissue, or umbilical cord concentrate
- 2. History of knee injection with hyaluronic acid or hylan within the past year
- 3. History of percutaneous invasive knee procedure in the past 3 months
- 4. Sepsis
- 5. Skin integrity alterations or infection of the knee or iliac crest
- 6. Inability to walk and perform transfers independently
- 7. Known immunosuppression, due to disease or therapy
- 8. Active oncological disease in the affected knee or in the iliac bone
- 9. Active infectious disease or fever
- 10. Depression
- 11. Fibromyalgia
- 12. Severe mental illness
- 13. Severe cognitive impairment

#### Date of first enrolment

10/12/2025

#### Date of final enrolment

10/12/2026

# Locations

#### Countries of recruitment

Portugal

# Study participating centre Unidade Local de Saúde de Lisboa Ocidental

Estrada do Forte do Alto do Duque Lisboa Portugal 1449-005

# Sponsor information

## Organisation

Universidade Nova de Lisboa

#### **ROR**

https://ror.org/02xankh89

#### Organisation

Centro Hospitalar de Lisboa Ocidental

#### **ROR**

https://ror.org/036ypft38

# Funder(s)

Funder type

#### Funder Name

Centro Clínico Académico de Lisboa (CCAL), Lisbon Clinical Academic Centre, Portugal

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not expected to be made available